9PT Stock Chart & Stats
€0.93
<€0.01(0.86%)
At close: 4:00 PM EDT
€0.93
<€0.01(0.86%)
Day’s Range― - ―
52-Week Range€0.85 - €1.63
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€56.37M
Enterprise Value-€58.77M
Total Cash (Recent Filing)€158.10M
Total Debt (Recent Filing)€28.74M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Nov 05, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding61,921,898
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-0.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.23Price Target Upside139.92% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-1.25
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Narrowing LossesThe substantial reduction in net losses indicates improving expense discipline or better spending efficiency as Pliant advances its pipeline. Although profitability remains distant, a smaller loss base can extend financial flexibility and reduce the pace at which the company consumes capital over the next several quarters.
Modest LeverageRelatively modest debt reduces fixed financial obligations while the company remains pre-commercial and loss-making. This provides more balance-sheet flexibility than a highly leveraged structure and may help management prioritize research programs without the additional pressure of substantial interest or refinancing commitments.
Strengthened R&D GovernanceAdding independent directors with dedicated research and development oversight strengthens governance around pipeline strategy and scientific decision-making. Their experience and committee roles could improve board scrutiny of development priorities, an enduring capability for a clinical-stage company dependent on successful research execution.
Bears Say
No Commercial Revenue BasePliant remains pre-commercial, so it lacks recurring product revenue to fund operations or validate commercial demand. This leaves financial performance heavily dependent on advancing clinical programs and obtaining future financing, while also limiting earnings visibility over the next several quarters.
Persistent Cash BurnContinued negative operating and free cash flow means the business is still consuming capital rather than generating internally funded resources. Even with burn moderating from 2024 and 2025 levels, ongoing research spending will likely require sustained funding and constrains the company’s ability to self-finance development.
Equity Erosion And Financing RiskThe sharp reduction in equity reflects the cumulative effect of ongoing losses and cash consumption. If this trajectory persists, Pliant may need additional external capital to continue development, creating financing and potential dilution risk while weakening the balance-sheet cushion available to absorb setbacks.
Pliant Therapeutics News
9PT FAQ
What was Pliant Therapeutics’s price range in the past 12 months?
Pliant Therapeutics lowest stock price was €0.85 and its highest was €1.63 in the past 12 months.
What is Pliant Therapeutics’s market cap?
Pliant Therapeutics’s market cap is €56.37M.
When is Pliant Therapeutics’s upcoming earnings report date?
Pliant Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 25 days.
How were Pliant Therapeutics’s earnings last quarter?
Pliant Therapeutics released its earnings results on Aug 11, 2026. The company reported -€0.321 earnings per share for the quarter, missing the consensus estimate of -€0.305 by -€0.016.
Is Pliant Therapeutics overvalued?
According to Wall Street analysts Pliant Therapeutics’s price is currently Undervalued.
Does Pliant Therapeutics pay dividends?
Pliant Therapeutics does not currently pay dividends.
What is Pliant Therapeutics’s EPS estimate?
Pliant Therapeutics’s EPS estimate is -0.33.
How many shares outstanding does Pliant Therapeutics have?
Pliant Therapeutics has 61,921,898 shares outstanding.
What happened to Pliant Therapeutics’s price movement after its last earnings report?
Pliant Therapeutics reported an EPS of -€0.321 in its last earnings report, missing expectations of -€0.305. Following the earnings report the stock price went down -2.876%.
Which hedge fund is a major shareholder of Pliant Therapeutics?
Currently, no hedge funds are holding shares in DE:9PT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pliant Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.76%
12-Months-Change
Fundamentals
Return on Equity
-53.22%
Trailing 12-Months
Asset Growth
-36.67%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pliant Therapeutics
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
9PT Stock 12 Month Forecast
Average Price Target
€2.23
▲(139.92% Upside)
Technical Analysis
aTyr Pharma
―
Rein Therapeutics
―
Gossamer Bio
―
Aligos Therapeutics
―
Fractyl Health, Inc.
―